HKT-288

N/A

Report date: 2024/02/05 13:59:11

Base Information

Drug NameHKT-288

Drug Alias NameNOV-13HKT-288

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > SPDB linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM4 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAlkylating agentsDNA cross linking agentsAnti-Cadherin-6

TargetsDNACadherin-6

Therapy Area/IndicationsCarcinoma, Ovarian EpithelialCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited StatesAustralia +[6]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNovartis Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNovartis Pharma Ag

Active IndicationsN/A

Inactive IndicationsCarcinoma, Ovarian EpithelialCarcinoma, Renal Cell

Other Information

ATC CodeN/A